Can you take Freeze It with Naloxegol?
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- Freeze It (camphor/menthol topical)
- naloxegol
Drug interactions
Minor drug interactions
Minor:
menthol topical naloxegol
Applies to: Freeze It (camphor / menthol topical) and naloxegol
Information for this minor interaction is available on the professional version.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
naloxegol Food/Lifestyle
Applies to: naloxegol
Do not consume grapefruit or grapefruit juice during treatment with naloxegol. Grapefruit juice can significantly increase the blood levels of naloxegol. You may be more likely to experience side effects and withdrawal symptoms such as sweating, tearing, runny nose, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning. Taking naloxegol with food can also increase its absorption into the blood stream. Therefore, you should take it on an empty stomach at least 1 hour before or 2 hours after a meal. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
6 potential interactions Applies to: 6 conditions, including Diverticulitis, Inflammatory Bowel Disease, Peptic Ulcer, Liver Disease, and Renal Dysfunction.
Diverticulitis
Major:
naloxegol
Naloxegol has a major potential interaction with Diverticulitis.
Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation. Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn's disease, infiltrative GI tract malignancies or peritoneal metastases. It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms. The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.
Gastrointestinal Obstruction
Major:
naloxegol
Naloxegol has a major potential interaction with Gastrointestinal Obstruction.
Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation. Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn's disease, infiltrative GI tract malignancies or peritoneal metastases. It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms. The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.
Inflammatory Bowel Disease
Major:
naloxegol
Naloxegol has a major potential interaction with Inflammatory Bowel Disease.
Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation. Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn's disease, infiltrative GI tract malignancies or peritoneal metastases. It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms. The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.
Liver Disease
Major:
naloxegol
Naloxegol has a major potential interaction with Liver Disease.
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of naloxegol has not been evaluated, so the use of this drug should be avoided in patients with this condition. No dose adjustment is required for patients with mild or moderate hepatic impairment.
Peptic Ulcer
Major:
naloxegol
Naloxegol has a major potential interaction with Peptic Ulcer.
Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation. Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn's disease, infiltrative GI tract malignancies or peritoneal metastases. It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms. The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.
Renal Dysfunction
Moderate:
naloxegol
Naloxegol has a moderate potential interaction with Renal Dysfunction.
Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function. A dose reduction is recommended for these patients. No dosage adjustment is needed in patients with mild renal impairment.
Report options
More resources
Freeze It
A total of 364 drugs are known to interact with Freeze It.
- Freeze it is in the drug class topical rubefacient.
- Freeze it is used to treat the following conditions:
naloxegol
A total of 264 drugs are known to interact with naloxegol.
- Naloxegol is in the drug class peripheral opioid receptor antagonists.
- Naloxegol is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.